Save Product
Product Details
Synonyms
Delta3, delta-like 3 (Drosophila), delta-like protein 3, DLL3, Pudgy, SCDO1, SCDO1delta3
Source
Human DLL3 (312-492) , His Tag (DL3-H52Hz) is expressed from human 293 cells (HEK293). It contains AA Ser 312 - Leu 492 (Accession # Q9NYJ7-1).
Predicted N-terminus: Ser 312
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 20.4 kDa. The protein migrates as 21-25 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 0.01 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
Formulation
Supplied as 0.2 μm filtered solution in PBS, pH7.4.
Contact us for customized product form or formulation.
Shipping
This product is supplied and shipped with dry ice, please inquire the shipping cost.
Storage
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 3 months under sterile conditions.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Human DLL3 (312-492) , His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
Bioactivity-ELISA
Immobilized Human DLL3 (312-492) , His Tag (Cat. No. DL3-H52Hz) at 1 μg/mL (100 μL/well) can bind Anti-DLL3 Antibody (specific Binding EGFs of DLL3), Human IgG1 with a linear range of 0.1-2 ng/mL (Routinely tested).
Protocol
Bioactivity-SPR
Anti-DLL3 Antibody (specific Binding EGF5 of DLL3), Human IgG1 captured on Protein A Chip can bind Human DLL3 (312-492) , His Tag (Cat. No. DL3-H52Hz) with an affinity constant of 0.342 nM as determined in a SPR assay (Biacore 8K) (QC tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Drug Development Progress- English Name：
Delta-like protein 3
- Category：
- Approved Drugs：
1 Details
- Drugs in Clinical Trials：
28 Details
- Highest Development Stage：
Approved
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
